Table 2 Survival analysis of cervical cancer patients treated with pelvic exenteration due to cancer recurrence
From: Analysis of long-term outcomes in 44 patients following pelvic exenteration due to cervical cancer
Pelvic exenteration in cervical cancer recurrence | |||
|---|---|---|---|
Median (months) | IQR | P value | |
Initial FIGO stage of the disease | |||
IB, IIA, and IIB (n = 13) | 11.4 | 5.5-41.4 | 0.70 |
IIIA and IIIB (n = 10) | 16.4 | 3.8-17.1 | |
IVA and IVB (n = 9) | 12.3 | 7.7-13.3 | |
Type of pelvic exenteration | |||
Anterior (n = 6) | 12.2 | 5.9-19.7 | 0.88 |
Total (n = 22) | 11.5 | 5-17.1 | |
Posterior (n = 4) | 12.3 | 6.7-21.8 | |
Survival in relationship to histopathological type of cervical cancer | |||
Squamous cell carcinoma (n = 17) | 20.5 | 4.9-33.1 | 0.01 |
Adenocarcinoma (n = 14) | 10.7 | 5.9-13.3 | |
Vaginal fistula | |||
Absent (n = 28) | 11.5 | 4.7-15.6 | 0.02 |
Present (n = 4) | Not reached | 16.0-55.6 | |
The need of repeated surgery | |||
Reoperation within 30 days (n = 6) | 4.5 | 3.2-10.7 | 0.02 |
No reoperation within 30 days (n = 26) | 13.3 | 5.9-19.7 | |
Adverse events | |||
Severe adverse events (n = 11) | 10.4 | 4.1-11.3 | 0.03 |
No severe adverse events (n = 21) | 19.3 | 8.8-25.9 | |
Specimen margins status | |||
Positive margins (n = 5) | 7.7 | 6.6-16.5 | 0.09 |
Negative margins (n = 27) | 12.3 | 4.7-16.6 | |
Lymph node metastases | |||
Absent (n = 26) | 12.3 | 4.3-19.5 | 0.55 |
Present (n = 6) | 11.5 | 6.2-13.1 | |
Time to recurrence | |||
0-12 months (n = 10) | 13.3 | 7.7-19.3 | 0.31 |
12-36 months (n = 14) | 16.4 | 4.7-17.5 | |
Above 36 months (n = 8) | 10.6 | 6.6-15.6 | |
History of hysterectomy during initial treatment | |||
Hysterectomy performed (n = 3) | 7.4 | 1.1-78.7* | 0.78 |
No hysterectomy (n = 29) | 12.3 | 4.8-18.0 | |